<?xml version='1.0' encoding='utf-8'?>
<document id="28685967"><sentence text="Rapid solid-phase extraction coupled with GC-MS method for the determination of venlafaxine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine."><entity charOffset="80-91" id="DDI-PubMed.28685967.s1.e0" text="venlafaxine" /><entity charOffset="173-184" id="DDI-PubMed.28685967.s1.e1" text="venlafaxine" /><entity charOffset="199-209" id="DDI-PubMed.28685967.s1.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28685967.s1.e0" e2="DDI-PubMed.28685967.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28685967.s1.e0" e2="DDI-PubMed.28685967.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28685967.s1.e0" e2="DDI-PubMed.28685967.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28685967.s1.e1" e2="DDI-PubMed.28685967.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28685967.s1.e1" e2="DDI-PubMed.28685967.s1.e2" /></sentence><sentence text="A rapid and sensitive gas chromatography with mass spectrometry method for the determination of venlafaxine in rat plasma has been developed and applied to a drug-drug interaction study of fluoxetine on pharmacokinetics of venlafaxine in rats"><entity charOffset="96-107" id="DDI-PubMed.28685967.s2.e0" text="venlafaxine" /><entity charOffset="189-199" id="DDI-PubMed.28685967.s2.e1" text="fluoxetine" /><entity charOffset="223-234" id="DDI-PubMed.28685967.s2.e2" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.28685967.s2.e0" e2="DDI-PubMed.28685967.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28685967.s2.e0" e2="DDI-PubMed.28685967.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28685967.s2.e0" e2="DDI-PubMed.28685967.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28685967.s2.e1" e2="DDI-PubMed.28685967.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28685967.s2.e1" e2="DDI-PubMed.28685967.s2.e2" /></sentence><sentence text=" Rat plasma was spiked with 2% aqueous ammonia before subjected to preactivated C18 solid-phase extraction columns and eluted with methanol"><entity charOffset="39-46" id="DDI-PubMed.28685967.s3.e0" text="ammonia" /><entity charOffset="131-139" id="DDI-PubMed.28685967.s3.e1" text="methanol" /><pair ddi="false" e1="DDI-PubMed.28685967.s3.e0" e2="DDI-PubMed.28685967.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28685967.s3.e0" e2="DDI-PubMed.28685967.s3.e1" /></sentence><sentence text=" No endogenous interferences were observed under optimal condition" /><sentence text=" The calibration curve was linear (R2  = 0" /><sentence text="9994) in the range of 10-1000 ng/mL" /><sentence text=" The quantification limit of venlafaxine in rat plasma was 10 ng/mL"><entity charOffset="29-40" id="DDI-PubMed.28685967.s7.e0" text="venlafaxine" /></sentence><sentence text=" The accuracy was in the range of 85-110%, and the extraction recovery was no less than 50%" /><sentence text=" Both the intra- and interday precision were 5" /><sentence text="0-10" /><sentence text="7%" /><sentence text=" The concentration-time curve showed that plasma concentrations of the coadministration group (group B) were higher than that of single dose group (group A)" /><sentence text=" Both values of Cmax (0" /><sentence text="069 mg/L) and AUC0→∞ (0" /><sentence text="291 mg h/L) in group B were statistically greater than that of Cmax (0" /><sentence text="046 mg/L) and AUC0→∞ (0"><entity charOffset="14-20" id="DDI-PubMed.28685967.s16.e0" text="AUC0→∞" /></sentence><sentence text="181 mg·h/L) in group A (P &lt; 0" /><sentence text="05)" /><sentence text=" The results indicated that a significant effect of fluoxetine was shown on the pharmacokinetics of venlafaxine, suggesting that drug-drug interactions are of concern for the treatment of depression with the combined use of venlafaxine and fluoxetine"><entity charOffset="52-62" id="DDI-PubMed.28685967.s19.e0" text="fluoxetine" /><entity charOffset="100-111" id="DDI-PubMed.28685967.s19.e1" text="venlafaxine" /><entity charOffset="224-235" id="DDI-PubMed.28685967.s19.e2" text="venlafaxine" /><entity charOffset="240-250" id="DDI-PubMed.28685967.s19.e3" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28685967.s19.e0" e2="DDI-PubMed.28685967.s19.e0" /><pair ddi="false" e1="DDI-PubMed.28685967.s19.e0" e2="DDI-PubMed.28685967.s19.e1" /><pair ddi="true" e1="DDI-PubMed.28685967.s19.e0" e2="DDI-PubMed.28685967.s19.e2" /><pair ddi="true" e1="DDI-PubMed.28685967.s19.e0" e2="DDI-PubMed.28685967.s19.e3" /><pair ddi="false" e1="DDI-PubMed.28685967.s19.e1" e2="DDI-PubMed.28685967.s19.e1" /><pair ddi="true" e1="DDI-PubMed.28685967.s19.e1" e2="DDI-PubMed.28685967.s19.e2" /><pair ddi="true" e1="DDI-PubMed.28685967.s19.e1" e2="DDI-PubMed.28685967.s19.e3" /><pair ddi="false" e1="DDI-PubMed.28685967.s19.e2" e2="DDI-PubMed.28685967.s19.e2" /><pair ddi="false" e1="DDI-PubMed.28685967.s19.e2" e2="DDI-PubMed.28685967.s19.e3" /></sentence><sentence text="" /></document>